BTN3A2, His & Avi, Human

BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial ovarian cancer (HG-EOC).In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with better outcome. In contrast, high CD206 /CD68 expression is associated with high risk of disease progression.

Price	$340.00
Cat. No.	Z05098-100
Size	100 μg 500 μg Buy in bulk
Quantity
Est. Delivery


Ask us a question

Product Introduction Background Bottom Notes

Product Introduction

Species

Human

Protein Construction

BTN3A2 (Gln30-Trp248) Accession # P78410-1	His	Avi
N-term		C-term

Purity

> 95% as determined by BisTris PAGE

Endotoxin Level

Less than 1EU per μg by the LAL method.

Expression System

HEK293

Theoretical Molecular Weight

26.5 kDa

Apparent Molecular Weight

Due to glycosylation, the protein migrates to 27-33 kDa based on Bis-Tris PAGE result.

Formulation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).

Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage & Stability

Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Back

The purity of BTN3A2, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »

BTN3A2, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

Background

Target Background

Synonyms

BT3.2; BTF3; BTF4; BT3.3; BTN3A2; FLJ40011; BTN3.2; CD277

Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.